raises IGF-1 and carries glucose-tolerance risk Compound Semaglutide (Wegovy) Class GLP-1 receptor agonist FDA Status FDA-approved for chronic weight management Evidence Strength Phase 3 RCTs
Home microneedling devices, including dermarollers and dermapens, offer a more accessible alternative
How long does it take to see results from this combination
Because it competes at the nicotinamide substrate site rather than the SAM cofactor site, it is also used as the substrate-competitive reference compound against which bisubstrate and covalent NNMT inhibitors are benchmarked
These symptoms are a sign that your body needs immediate and consistent support
Safety: what we know, what we dont What clinical trial safety reviews suggest The clinical safety review literature reports several reassuring signals: No meaningful increase in IGF-1 in monitored long-term studies (jofem.org) No clear negative effect on carbohydrate metabolism in testing described (contrast with full hGH) (jofem.org) No clear immunogenicity signal (e.g., anti-AOD antibodies) in the subset assessed in those trials (jofem.org) The major limitation: long-term real-world certainty is thin The problem with many peptides is not that everything is dangerousits that the certainty level is often lower than patients assume